AbbVie, the American pharmaceutical company, has confirmed the acquisition of Cerevel Therapeutics for an amount of $8.7 billion (€8.066 billion), according to a joint statement from both companies.
The transaction involves the purchase of all outstanding shares of Cerevel at a unit price of $45 in cash.
Both the boards of directors of AbbVie and Cerevel have approved the transaction, which is subject to approval by Cerevel shareholders, as well as regulatory approvals and other customary closing conditions.
The transaction is expected to be completed around mid-2024.
The acquisition of Cerevel is presented as a strategic move to strengthen AbbVie's neuroscience portfolio. This incorporation will include a broad range of assets designed to transform the standards of care in psychiatric and neurological disorders, such as schizophrenia and Parkinson's.
Richard A. González, president and chief executive officer of AbbVie, expressed that the company will leverage its solid commercial capabilities, international presence, and clinical and regulatory expertise to generate substantial value for shareholders.
This acquisition adds to another recent announcement by AbbVie about the purchase of ImmunoGen for a value of $10.1 billion (€9.193 billion), thus consolidating the company's position in the pharmaceutical market.
Information from: Infobae
Receive all industry news in our weekly Newsletter Scientific Dialectics.